Im Keon-Il, Park Min-Jung, Kim Nayoun, Lim Jung-Yeon, Park Hyun-Sil, Lee Sung-Hee, Nam Young-Sun, Lee Eun-Sol, Lee Jung-Ho, Cho Mi-La, Cho Seok-Goo
1 Laboratory of Immune Regulation, Convergent Research Consortium for Immunologic Disease, The Catholic University of Korea College of Medicine , Seoul, Korea.
Stem Cells Dev. 2014 Oct 1;23(19):2364-76. doi: 10.1089/scd.2013.0617. Epub 2014 Jun 26.
Establishment of mixed chimerism is an ideal approach to induce donor-specific tolerance while expanding its potential in various clinical settings. Despite the developments in partial conditioning regimens, improvements are still needed in reducing toxicity and bone marrow transplantation-related complications. Recently, cell-based therapies, including mesenchymal stem cells (MSCs), have been incorporated in establishing noncytoreductive mixed chimerism protocols; however, its efficacy is only partial and shows reversed immunosuppressive properties. This study demonstrates a novel approach to induce mixed chimerism and tolerance through combinatory cell-based immune modulation (CCIM) of MSCs and regulatory T cells (Tregs). We hypothesize that the interaction between these cells may lead to greater inhibition of host immune responses. Compared with single cell therapy, CCIM induced a higher engraftment rate and robust donor-specific tolerance to skin allografts across full major histocompatibility complex barriers. These regulatory effects were associated with inhibition of natural killer cell cytotoxic activity, CD4(+)IL-17(+) cells, memory B cells, plasma cells, and immunoglobulin production levels along with increased frequencies of CD4(+)Foxp3(+) cells, IL-10-producing mature B cells, and myeloid-derived suppressor cells. Furthermore, CCIM was able to regulate mortality in a graft-versus-host disease model through reciprocal regulation of Treg/Th17. Taken together, we suggest CCIM as a clinically applicable strategy for facilitating the induction of mixed chimerism and permanent tolerance.
建立混合嵌合体是诱导供体特异性耐受并扩大其在各种临床环境中潜力的理想方法。尽管部分预处理方案有所发展,但在降低毒性和骨髓移植相关并发症方面仍需改进。最近,包括间充质干细胞(MSCs)在内的基于细胞的疗法已被纳入建立非细胞减灭性混合嵌合体方案中;然而,其疗效仅为部分有效,且显示出相反的免疫抑制特性。本研究展示了一种通过间充质干细胞和调节性T细胞(Tregs)的联合细胞免疫调节(CCIM)诱导混合嵌合体和耐受的新方法。我们假设这些细胞之间的相互作用可能导致对宿主免疫反应的更大抑制。与单细胞疗法相比,CCIM诱导了更高的植入率,并在完整的主要组织相容性复合体屏障上对皮肤同种异体移植物产生了强大的供体特异性耐受。这些调节作用与自然杀伤细胞细胞毒性活性、CD4(+)IL-17(+)细胞、记忆B细胞、浆细胞和免疫球蛋白产生水平的抑制相关,同时CD4(+)Foxp3(+)细胞、产生IL-10的成熟B细胞和骨髓来源的抑制细胞的频率增加。此外,CCIM能够通过Treg/Th17的相互调节来调节移植物抗宿主病模型中的死亡率。综上所述,我们建议将CCIM作为一种临床适用策略,以促进混合嵌合体的诱导和永久耐受。